@article{ddd.uab.cat:281324,
author = {Ortiz, Raquel and Barajas Vélez, Ana and Pons-Grífols, Anna
and Trinité, Benjamin and Tarrés-Freixas, Ferran and Rovirosa,
Carla and Urrea, Víctor and Barreiro Vázquez, Antonio and
Gonzalez-Tendero, Anna and Cardona, Maria and Ferrer, Laura and
Clotet Sala, Bonaventura and Carrillo, Jorge and Aguilar-
Gurrieri, Carmen and Blanco, Julià},
title = {Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis
of Production and Immunogenicity},
journal = {International journal of molecular sciences},
year = {2023},
volume = {24},
month = {5},
abstract = {Feline leukemia virus (FeLV) is one of the most prevalent
infectious diseases in domestic cats. Although different
commercial vaccines are available, none of them provides full
protection. Thus, efforts to design a more efficient vaccine are
needed. Our group has successfully engineered HIV-1 Gag-based
VLPs that induce a potent and functional immune response against
the HIV-1 transmembrane protein gp41. Here, we propose to use
this concept to generate FeLV-Gag-based VLPs as a novel vaccine
strategy against this retrovirus. By analogy to our HIV-1
platform, a fragment of the FeLV transmembrane p15E protein was
exposed on FeLV-Gag-based VLPs. After optimization of Gag
sequences, the immunogenicity of the selected candidates was
evaluated in C57BL/6 and BALB/c mice, showing strong cellular and
humoral responses to Gag but failing to generate anti-p15E
antibodies. Altogether, this study not only tests the versatility
of the enveloped VLP-based vaccine platform but also sheds light
on FeLV vaccine research.},
doi = {10.3390/ijms24109025},
url = {https://ddd.uab.cat/record/281324},
}